Date receipt dossier
Company / Sponsor
Schering Plough NV/SA
Phase
II
Treated organism
Humans
Indication category
Cancer therapy
Disease
Non-Small Cell Lung Cancer
Therapeutic approach
Tumor suppressor gene
Genetic modification
Wild-type p53
Method of transfer of nucleic acid of interest
Human Adenovirus serotype 5
Administered biological material
Recombinant Adenovirus D (E3, E1A, E1B, pIX)
Route of administration
Intratumoral
Locations in Belgium
Akademisch Ziekenhuis, Vrije Universiteit Brussel
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
I97-076-03